E. Brown

发表

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

S. Whittaker, P. Tanière, C. Harwood, 2013, The British journal of dermatology.

DNA repair and replication proteins as prognostic markers in melanoma

J. Bartlett, Liang Song, D. Melton, 2013, Histopathology.

Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases.

S. Wigmore, E. Harrison, E. Brown, 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.

FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, BRAF and PIK3CA

R. Butler, P. Quirke, H. Wasan, 2017 .

Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells.

I. Jurisica, M. Tsao, L. Penn, 2007, Proceedings of the National Academy of Sciences of the United States of America.

Association of galectin-3 expression with melanoma progression and prognosis.

J. Bartlett, D. Melton, J. Smyth, 2012, European journal of cancer.

Carcinosarcoma of the ovary

H. Gabra, M. Bradburn, J. Smyth, 2004, Cancer.

LBA21 Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial (EPOCH study)

C. Sofocleous, M. Mulcahy, P. Ross, 2021, Annals of Oncology.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

Performance of prediction models on survival outcomes of colorectal cancer with surgical resection: A systematic review and meta-analysis.

H. Campbell, E. Theodoratou, S. Farrington, 2019, Surgical oncology.

Integrin α11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells

I. Jurisica, M. Tsao, L. Penn, 2007, Proceedings of the National Academy of Sciences.

Glycosylation of plasma IgG in colorectal cancer prognosis

Pauline M. Rudd, Felix Agakov, Harry Campbell, 2016, Scientific Reports.

Concerns regarding BRAF testing algorithm: reply from authors

S. Whittaker, P. Tanière, C. Harwood, 2013, The British journal of dermatology.

Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial

Matthew S. Johnson, C. Sofocleous, Tae-You Kim, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

M. Parmar, R. Butler, J. Graham, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fascin expression is increased in metastatic lesions but does not correlate with progression nor outcome in melanoma

O. Sansom, D. Melton, Yafeng Ma, 2015, Melanoma research.

Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.

G. Pond, John Calvin Reed, M. Konopleva, 2006, Cancer research.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2018 .

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

T. Hickish, N. Heaton, O. Garden, 2020, The Lancet. Oncology.

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

M. Parmar, R. Butler, J. Graham, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib in the treatment of non-small cell lung cancer

F. Shepherd, E. Brown, 2005, Expert review of anticancer therapy.

Bcl-B Expression in Human Epithelial and Nonepithelial Malignancies

J. Winter, M. Duffy, John Calvin Reed, 2008, Clinical Cancer Research.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2017, The lancet. Gastroenterology & hepatology.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF , PIK3CA , KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2018 .

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial

R. Butler, S. Richman, L. Samuel, 2018 .

Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors

D. Melton, T. Brenn, E. Brown, 2012, British Journal of Cancer.

Receptors Tumor Cells to Tumor Necrosis Factor-Family Death Identification of Small Molecules that Sensitize Resistant

G. Pond, John Calvin Reed, M. Konopleva, 2006 .

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

L. Fearfield, E. Brown, J. Marsden, 2013, The British journal of dermatology.

Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.

G. Pond, John Calvin Reed, M. Konopleva, 2006, Cancer research.